ArticleFrontiers in oncology2025
Predictive model based on blood cell analysis and coagulation function indicators for neuroblastic tumors staging diagnosis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the diagnostic value of integrating blood cell analysis and coagulation function indicators in the staging of neuroblastic tumors, providing a robust basis for clinical decision-making. Methods: A retrospective analysis was conducted on 137 pediatric neuroblastic tumors cases (2017-2024) at the Children's Hospital Affiliated to Shandong University. Patients were stratified into localized (INSS 1-2, Group 1) and advanced (INSS 3-4, Group 2) stages according to the INSS classification, with mature ganglioneuroma serving as the control group. Univariate and multivariate logistic regression analyses were performed to identify differences in blood cell analysis and coagulation function indicators between groups, complemented by ROC curve analysis to evaluate the efficacy of the models. Results: The median age of patients with neuroblastic tumor was 23.5 (12-46.75) months (male:female = 1.55:1), which was significantly younger than that of ganglioneuroma patients [72 (53-108) months, Conclusion: The combined analysis of age, RDW-CV, Hb, Mon#, Fib, and TT can effectively assist in the preliminary assessment of whether children with neuroblastic tumors are in an advanced phase or suffering from ganglioneuroma. This method enhances the accuracy and efficiency of clinical diagnosis and serves as a crucial reference for developing disease diagnosis and treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.